KR20060113700A - 2,4-디옥소-3-퀴나졸리닐아릴 설포닐우레아 - Google Patents

2,4-디옥소-3-퀴나졸리닐아릴 설포닐우레아 Download PDF

Info

Publication number
KR20060113700A
KR20060113700A KR1020067008644A KR20067008644A KR20060113700A KR 20060113700 A KR20060113700 A KR 20060113700A KR 1020067008644 A KR1020067008644 A KR 1020067008644A KR 20067008644 A KR20067008644 A KR 20067008644A KR 20060113700 A KR20060113700 A KR 20060113700A
Authority
KR
South Korea
Prior art keywords
alkyl
group
alkoxy
cycloalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067008644A
Other languages
English (en)
Korean (ko)
Inventor
로버트 엠. 스카보로우
울린 후앙
안젤리 판데이
쇼운 엠. 바우어
자오밍 쟁
쟈오젱 제이. 지아
Original Assignee
포톨라 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포톨라 파마슈티컬스, 인코포레이티드 filed Critical 포톨라 파마슈티컬스, 인코포레이티드
Publication of KR20060113700A publication Critical patent/KR20060113700A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020067008644A 2003-10-03 2004-09-29 2,4-디옥소-3-퀴나졸리닐아릴 설포닐우레아 Ceased KR20060113700A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50856403P 2003-10-03 2003-10-03
US60/508,564 2003-10-03

Publications (1)

Publication Number Publication Date
KR20060113700A true KR20060113700A (ko) 2006-11-02

Family

ID=34421757

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067008644A Ceased KR20060113700A (ko) 2003-10-03 2004-09-29 2,4-디옥소-3-퀴나졸리닐아릴 설포닐우레아

Country Status (15)

Country Link
US (1) US7109332B2 (enExample)
EP (1) EP1668002B1 (enExample)
JP (1) JP2007507551A (enExample)
KR (1) KR20060113700A (enExample)
CN (1) CN1863798B (enExample)
AT (1) ATE448222T1 (enExample)
AU (1) AU2004278030C1 (enExample)
CA (1) CA2540214A1 (enExample)
DE (1) DE602004024093D1 (enExample)
ES (1) ES2334795T3 (enExample)
IL (1) IL174446A (enExample)
MX (1) MXPA06003618A (enExample)
PL (1) PL1668002T3 (enExample)
PT (1) PT1668002E (enExample)
WO (1) WO2005032488A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933236B2 (en) * 2012-05-22 2015-01-13 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
KR101194176B1 (ko) * 2003-12-22 2012-10-24 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체
WO2006039212A2 (en) * 2004-09-29 2006-04-13 Portola Pharmaceuticals, Inc. Substituted 2h-1,3-benzoxazin-4(3h)-ones
EA017402B1 (ru) * 2005-11-03 2012-12-28 Портола Фармасьютикалз, Инк. [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
JP2010523590A (ja) 2007-04-05 2010-07-15 ギリアード・パロ・アルト・インコーポレイテッド Ａｌｄｈ−２阻害剤としてのキナゾリノン誘導体
EP2138482A4 (en) 2007-04-19 2011-06-15 Astellas Pharma Inc BICYCLIC HETEROCYCLIC COMPOUND
EA200901474A1 (ru) * 2007-05-02 2010-04-30 Портола Фармасьютиклз, Инк. Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
CN101654441B (zh) * 2008-08-19 2012-10-03 信谊药厂 抗凝化合物、组合物及其用途
MX2011007681A (es) 2009-01-19 2011-08-08 Abbott Lab Agentes inducidores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes.
CN104945311A (zh) 2009-01-19 2015-09-30 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
JP6014154B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
WO2013064984A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
KR20150131233A (ko) 2013-03-14 2015-11-24 제넨테크, 인크. 치환된 트리아졸로피리딘 및 이의 사용 방법
US9493429B2 (en) 2013-03-15 2016-11-15 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
CR20160296A (es) 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
IL253661B2 (en) 2015-02-16 2024-01-01 Univ Queensland Sulfonylureas bearing a five-membered ring, and pharmaceutical compositions and uses thereof
EP3297989A1 (en) 2015-05-22 2018-03-28 Genentech, Inc. Substituted benzamides and methods of use thereof
CN108137477A (zh) 2015-08-27 2018-06-08 基因泰克公司 治疗化合物及其使用方法
CN108290881B (zh) 2015-09-28 2021-12-07 健泰科生物技术公司 治疗性化合物和其使用方法
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
US10766858B2 (en) 2016-03-30 2020-09-08 Genentech, Inc. Substituted benzamides and methods of use thereof
MX388175B (es) 2016-10-17 2025-03-19 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
DK3661925T3 (da) 2017-07-07 2022-02-28 Inflazome Ltd Hidtil ukendte sulfonamidcarboxamidforbindelser
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
MA49903A (fr) 2017-08-15 2020-06-24 Inflazome Ltd Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
MA50567A (fr) 2017-11-09 2020-09-16 Inflazome Ltd Nouveaux composés de sulfonamide carboxamide
CN112041313A (zh) 2018-02-26 2020-12-04 基因泰克公司 吡啶-磺酰胺化合物及其针对疼痛和相关疾患的用途
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
JP2021519788A (ja) 2018-03-30 2021-08-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
US20230030720A1 (en) 2018-12-06 2023-02-02 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
WO1999036425A1 (en) 1998-01-15 1999-07-22 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
DK1257550T3 (da) * 2000-02-04 2006-03-27 Portola Pharm Inc Blodplade-ADP-receptor-inhibitor

Also Published As

Publication number Publication date
AU2004278030A1 (en) 2005-04-14
ATE448222T1 (de) 2009-11-15
CN1863798B (zh) 2011-08-31
WO2005032488A2 (en) 2005-04-14
IL174446A (en) 2012-02-29
EP1668002B1 (en) 2009-11-11
EP1668002A4 (en) 2006-12-20
EP1668002A2 (en) 2006-06-14
CN1863798A (zh) 2006-11-15
ES2334795T3 (es) 2010-03-16
DE602004024093D1 (de) 2009-12-24
JP2007507551A (ja) 2007-03-29
PL1668002T3 (pl) 2010-02-26
AU2004278030C1 (en) 2010-12-02
PT1668002E (pt) 2009-11-25
US20050107357A1 (en) 2005-05-19
WO2005032488A3 (en) 2005-05-12
AU2004278030B2 (en) 2010-07-01
CA2540214A1 (en) 2005-04-14
IL174446A0 (en) 2006-08-01
US7109332B2 (en) 2006-09-19
HK1093973A1 (en) 2007-03-16
MXPA06003618A (es) 2006-08-11

Similar Documents

Publication Publication Date Title
KR20060113700A (ko) 2,4-디옥소-3-퀴나졸리닐아릴 설포닐우레아
AU2005292314B2 (en) Substituted 2H-1,3-benzoxazin-4(3H)-ones
JP4574100B2 (ja) 血小板ａｄｐレセプターインヒビター
JP4879745B2 (ja) 置換イソキノリノン
JP5266232B2 (ja) 血小板ａｄｐ受容体阻害剤としての窒素含有置換ヘテロ環
HK1093973B (en) 2,4-dioxo-3-quinazolinylaryl sulfonylureas
CN101534832A (zh) 作为血小板adp受体抑制剂的被取代的含氮杂环类化合物
HK1131058B (en) Nitrogen containing substituted heterocycles as platelet adp receptor inhibitors
HK1111414B (en) Substituted 2h-1,3-benzoxazin-4(3h)-ones

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060503

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090928

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110511

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120521

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20121101

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120521

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20110511

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I